LOUISVILLE, Colo., April 17 /PRNewswire-FirstCall/ -- Replidyne, Inc. announced today that it will host a conference call on May 1, 2007 at 8:30 A.M. ET to report first quarter 2007 earnings. Additionally, Replidyne will present at three upcoming investor conferences in May 2007.
Earnings conference call information is as follows: Kenneth J. Collins, President and CEO, and other members of Replidyne’s senior management team will provide a company update and discuss earnings results via conference call and webcast on Tuesday, May 1, 2007, at 8:30 A.M. ET. Callers may participate in the conference call by dialing 866-831-6270 (domestic) or 617-213-8858 (international), and providing the passcode 76894926. To access the live webcast, please log on to the company’s website at www.Replidyne.com and go to the Investor Relations section. A replay of the conference call will be available approximately one hour after completion of the call through Tuesday, May 15, 2007 at midnight. Callers may access the replay by dialing 888-286-8010 (U.S. participants) or 617-801-6888 (international participants). The audio replay passcode is 34071436. To access a replay of the webcast, visit the Investor Relations section of the company’s website at www.Replidyne.com. Investor conference presentation information is as follows: * Mr. Collins will present on Thursday, May 3, at 1:30 P.M. E.T. at the Morgan Stanley Global Healthcare Unplugged Conference, to be held at the Ritz-Carlton in Key Biscayne, Florida. * Mr. Collins will present on Tuesday, May 15, at 8:20 A.M. C.E.S.T. at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference, to be held at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. * Mr. Collins will present on Tuesday, May 22, at 2:30 P.M. E.T. at the Citigroup 2007 Global Healthcare Conference, to be held at the Hilton Hotel in New York, New York.
A live audio webcast of each presentation will be available on the investor relations section of the company’s website at www.Replidyne.com. The webcasts will be archived and available on Replidyne’s website after each event for a period of 30 days.
About Replidyne, Inc.
Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne’s lead product, faropenem medoxomil, is a novel oral, community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne’s second drug candidate, REP8839, is a topical anti-infective product in Phase I development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne is also pursuing the development of other novel anti-infective products based on its in-house discovery research.
Safe Harbor
This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company’s ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company’s product candidates and the Company’s ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company’s ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company’s sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company’s Form 10-K filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC’s electronic data gather analysis and retrieval system (EDGAR) at www.sec.gov. All forward- looking statements made in the press release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements in the document.
Replidyne, Inc.
CONTACT: Sabrina B. Oei, Dir. Investor & Public Relations, of Replidyne,Inc., +1-303-996-5535
Web site: http://www.Replidyne.com/
